Drug intelligence / Profile preview

AS1602

Development stage: Preclinical
Lead developer: Zhongke Aishen Pharmaceutical

Overview

AS1602 is an early-stage drug candidate under development by Zhongke Aishen Pharmaceutical (Shenzhen Amshenn Biological Pharmaceutical). While it is listed in the company's pipeline, specific details regarding its molecular target, mechanism of action, and intended therapeutic indications have not been publicly disclosed. The developer, Zhongke Aishen Pharmaceutical, specializes in the research of death receptor (DR) and decoy receptor (DcR) pathways, with other pipeline assets like AS1501 targeting DR5 for cardiovascular and oncological conditions.

Beyond the preview

Go deeper on AS1602.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AS1602.

Explore the full profile